Drug Database
IV
IVIG (BT 681 5% / IVIG 5%, Biotest / IVIG 10%, Biotest)
✓ ApprovedGrifols, S.A. · Monoclonal Antibodies · Monoclonal Antibodies
What is IVIG?
IVIG is a monoclonal antibodies developed by Grifols, S.A.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
Drug Profile
| Brand Names | BT 681 5%, IVIG 5%, Biotest, IVIG 10%, Biotest |
| Company | Grifols, S.A. |
| Drug Class | Monoclonal Antibodies, Polyclonal Antibodies, Antibody |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
Sources: ClinicalTrials.gov, Grifols, S.A.
Therapeutic Indications
IVIG is developed for 8 unique indications across 5 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Nervous system disorders | Chronic inflammatory demyelinating polyradiculoneuropathy | ✓ Approved |
| Immune system disorders | Selective IgG subclass deficiency | ✓ Approved |
| Nervous system disorders | Multifocal motor neuropathy | ✓ Approved |
| Nervous system disorders | Guillain-Barre syndrome | ✓ Approved |
| Blood and lymphatic system disorders | Thrombocytopenia | ✓ Approved |
+3 more indications available with a free account
Sign up free to view all indications →Related Research Articles
Unable to load articles right now.